Dogwood Therapeutics, Inc.
DWTX
Last
$1.40
Day
-0.7%
1y
-74.8%
5y
-98.9%
52w
-80.0%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-0526d
EMA 21
1.57
EMA 50
1.73
EMA 200
2.44
20d high
-30.0%
5y high
-99.4%
5y range
0th
Positions held
Your positionsDWTX isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-6
Hold
avoid
Signal
Sell
Target
$1.66
Stop
$1.20
Stop distance
14.3%
Target vs last
+18.6%
Fundamentals
| Market cap | $47.93M | Enterprise value | $38.45M | Trailing P/E | 0.64 | Forward P/E | -0.22 |
| PEG | — | Price / book | 0.69 | Beta | 1.94 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -47.8% | ROA | -20.8% | Debt / equity | 0.00 |
| Current ratio | 3.89 | Free cash flow | -$16.36M | Analyst recommendation | none | Mean target | $14.00 |
| 52w high | $7.04 | 52w low | $1.28 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$11.5M | -$5.0M | -$3.8M | -$15.7M | -$3.8M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$4.9M | -$5.1M | -$3.8M | -$15.8M | -$3.9M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$34.3M | -$12.3M | -$5.3M | -$12.2M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$28.0M | -$12.2M | -$5.4M | -$12.3M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · Dogwood to Participate in the 2026 Maxim Growth Summit
2026-09-14 · Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial
2026-09-01 · Dogwood Therapeutics Nears Phase 2b Readout for Halneuron Neuropathic Pain Treatment
2026-08-13 · Dogwood Therapeutics Announces Second Quarter 2026 Financial Results
2026-07-20 · Dogwood Therapeutics Enrolls First 200 Patients in Phase 2b Neuropathic Pain Trial
Price (daily)
Full chart · RSI · MACD · patternsDWTX · daily-6.6% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin